Phio Pharmaceuticals Q3 2023 Earnings Report $2.48 -0.29 (-10.47%) As of 01/21/2025 04:00 PM Eastern Earnings HistoryForecast Phio Pharmaceuticals EPS ResultsActual EPS-$10.26Consensus EPS -$12.87Beat/MissBeat by +$2.61One Year Ago EPSN/APhio Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/APhio Pharmaceuticals Announcement DetailsQuarterQ3 2023Date11/9/2023TimeN/AConference Call ResourcesPHIO Earnings History Phio Pharmaceuticals Earnings HeadlinesPhio Pharma (NASDAQ:PHIO) Stock Quotes, Forecast and News SummaryJanuary 14, 2025 | benzinga.comWe Asked Retail What's Next For Phio Pharma After Monday's Blistering Rally: Most See More Room To RunJanuary 14, 2025 | msn.comTrump currency shock imminentTrump's Quiet $1.9 Trillion Move Against the Fed A small army of Americans, with Trump's support, has launched a $1.9 trillion move against the Fed. What comes next could have dramatic consequences.January 22, 2025 | Stansberry Research (Ad)Phio Pharma Shares Triple After Positive Trial Data for Cancer TreatmentJanuary 13, 2025 | marketwatch.comPhio Pharma Stock Quadruples On Positive Data From Cancer Treatment Trial: Retail’s ElatedJanuary 13, 2025 | msn.comPhio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)October 24, 2024 | theglobeandmail.comSee More Phio Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Phio Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Phio Pharmaceuticals and other key companies, straight to your email. Email Address About Phio PharmaceuticalsPhio Pharmaceuticals (NASDAQ:PHIO) engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts.View Phio Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why Amazon’s Next Earnings Could Trigger a Stock BreakoutS&P 500 Earnings Set to Shine: January's Critical Market TestCiena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead? Upcoming Earnings CSX (1/23/2025)Intel (1/23/2025)Texas Instruments (1/23/2025)Freeport-McMoRan (1/23/2025)General Electric (1/23/2025)Union Pacific (1/23/2025)Elevance Health (1/23/2025)Verizon Communications (1/24/2025)NextEra Energy (1/24/2025)American Express (1/24/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
